Navigation Links
Amylin Pharmaceuticals Comments on Shareholder 13-D Filing
Date:1/29/2009

SAN DIEGO, Jan. 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) confirmed today that it has reviewed an amended 13-D filing with the Securities and Exchange Commission from Amylin shareholder Icahn Capital LP and affiliated funds announcing their intent to nominate a slate of five directors to stand for election at the Company's 2009 annual meeting. Amylin has not yet received the required notice with respect to this action.

Amylin's Corporate Governance Committee is engaged in a process to recommend a slate for election at the Company's annual meeting. It is reviewing potential nominees suggested by shareholders as part of that process, including two individuals previously discussed with representatives of the Icahn funds. Once the process has been completed, Amylin's Board of Directors will formally recommend a slate of nominees that it believes will act in the best interest of all shareholders.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amylin Pharmaceuticals Reports 2008 Financial Results
2. Amylin Pharmaceuticals to Webcast Year-End Results
3. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
4. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
5. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
6. Lilly and Amylin Set Date and Time for Conference Call
7. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
8. Amylin Pharmaceuticals Reports First Quarter Financial Results
9. Amylin Pharmaceuticals Reports 2007 Financial Results
10. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
11. Amylin Pharmaceuticals to Present at Research & Development Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses ... time to shed lights on the variety of topics detailing why we appreciate nurses ... tackles why this career has gone from being in a major recession to one ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... the factors of a stroke, which we as a society can control and change. ... a stroke occurs nearly every 40 seconds within the United States. Plus, with an ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... has partnered with Mediaplanet to help educate the many who are unaware of ... section dedicated to aphasia will run within the “Stroke Awareness” campaign. , The ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... is bolstered by inspiring human interest stories, courtesy of leaders in the nursing ... tech within the industry, from leading advocates and associations—namely Jones & Bartlett Learning. ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... to students studying complementary medicine. Allison Outerbridge is this year’s Life University ... on May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 According ... by Type (3D, 2D, 4D), by Therapeutic Area (Oncology, ... End User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast ... global Medical Animation Market for the forecast period of ... USD 301.3 Million by 2021 from USD 117.3 Million ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today ... co-development agreement with Therawis Diagnostics GmbH to develop and commercialize ... develop and market PITX2 as a marker to predict effectiveness ... cancer patients. "We are pleased to partner with ...
(Date:5/25/2016)... 2016  According to Kalorama Information, the world ... 2015.  Though these are challenging times in the ... success for companies that remain optimistic and seek ... growth prospects medical device companies spend a higher ... (R&D) than do companies in other industries.  Also, ...
Breaking Medicine Technology: